Symptoms reported by COVID-19 cases at baseline and at follow-up. حسب Spela Kokelj (8356644)

الموضوعات:

Overview of the WeARTolerance program. حسب Ana Beato (20489933)

الموضوعات:

Innovation and night light in large and small cities. حسب Saul Estrin (8629173)

iKIR score decreases protection associated with protective class II genotypes in T1D. حسب Laura Mora-Bitria (20477525)

Study-related adverse events. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study flow chart. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study CONSORT diagram. حسب Benjamin R. Lewis (22279166)

الموضوعات:

This is the data set that we used to reach the conclusions drawn in the manuscript with related metadata and methods. حسب Farayi Kaseke (19560197)

STORMS microbiome reporting checklist. حسب Katrine Carlsen (5477300)

"…</p><p>Results</p><p>From 25 patients (median age 14.4 years) diagnosed with Crohn´s Disease (n = 16) or ulcerative colitis (n = 9), microbiota were analysed in 671 faecal samples collected across 15 treatment intervals.</p><p>A significant decrease over time in Shannon diversity, following the initial increase within four weeks of treatment, was found across patients. …"

Introgression decreases allelic shuffling. حسب Enrique J. Schwarzkopf (6579275)

Supplementary Material for: Longitudinal Decrease in Left Ventricular Size with Age: Impact on Mortality and Cardiovascular Hospitalization حسب figshare admin karger (2628495)

"…Participants were categorized by LVEDD change from baseline: No Change (<5 mm), Decreased (≥5 mm), and Increased (≥5 mm). Results: A decrease in LVEDD was observed in 24% of participants (mean change -9±3 mm) and was significantly associated with older age, female sex, decreased volumes, concentric remodeling and diastolic dysfunction. …"

Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Why does task performance decrease with burst length? حسب Swathi Anil (17382903)

Relative abundance (%) of the small placolith components in the studied interval of core SO130-289KL. حسب Jose Dominick Guballa (19739909)

الموضوعات:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Primary and secondary efficacy end points (intention-to-treat population). حسب Benjamin R. Lewis (22279166)

الموضوعات:

Demographic and clinical characteristics of participants at baseline. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in Demoralization Scale (DSII) by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات: